PUBLIC COMPANY
saveSeagen Inc
updated 2mo ago
Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, was considered the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells, with its development of drugs such as Adcetris, Padcev, and Tivdak.
community read0 votes
pipeline
2
marketed
1
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Marketed1Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
- phase2Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
- —Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors
- phase2A Study of SEA-CD40 Given With Other Drugs in Cancers
- phase2A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
- phase1A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
- phase1A Study of SGN-ALPV in Advanced Solid Tumors
- phase1A Study of SGN-STNV in Advanced Solid Tumors
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that